Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Yongxian Hu, Yali Zhou, Mingming Zhang, Shan Fu, Yong Yu, Ming Gao, Ruimin Hong, Houli Zhao, Lu Han, Jiangtao Ren, He Huang

Blood (2024) 144 (Supplement 1): 921.

https://doi.org/10.1182/blood-2024-207322

Published: 2024

Journal Articles

APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial

Wenxiao Li, Yongxian Hu, Mingming Zhang, Xinyi Lai, Mengyu Zhao, Shan Fu, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2024-209660

Published: 2024

Journal Articles

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Yongxian Hu, Mingming Zhang, Shan Fu, Ruimin Hong, Jiazhen Cui, Simao Huang, Min Gao, Daojun Bai, Jingjing Ren, Xingbing Wang, Yugang Guo, Li Tang, He Huang

Blood (2024) 144 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2024-207694

Published: 2024

Journal Articles

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2024-209418

Published: 2024

Journal Articles

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2 ) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 91.

https://doi.org/10.1182/blood-2024-210462

Published: 2024

Journal Articles

Targeting Mitophagy Enhances Cytotoxicity of Autologously-Derived CAR-T Cells

Rongrong Chen, Mingming Zhang, Xufeng Cen, Chunxiang Jin, Yi Luo, Hongguang Xia, Rongqing Pan, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 7137.

https://doi.org/10.1182/blood-2024-203326

Published: 2024

Journal Articles

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2024-210124

Published: 2024

Journal Articles

CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study

Jinglei Yu, Fengmei Song, Mingming Zhang, Mingfeng Zhao, Wei Sang, Songfu Jiang, Lixin Wang, Xingbing Wang, He Huang, Yongxian Hu, Guoqing Wei

Blood (2024) 144 (Supplement 1): 4201.

https://doi.org/10.1182/blood-2024-210616

Published: 2024

Journal Articles

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

Yongxian HU, Guoqing Wei, Shan Fu, Pingnan Xiao, Jingjing Feng, Mingming Zhang, Xingbing Wang, Dongrui Wang, Jun Li, He Huang

Blood (2023) 142 (Supplement 1): 2111.

https://doi.org/10.1182/blood-2023-189052

Published: 2023

Journal Articles

Characteristics of Central Nervous System Relapse after CD19 CAR-T Cell Therapy in R/R NHL

Mengyu Zhao, Tingting Yang, Yetian Dong, Wenxiao Li, Tianning Gu, Linghui Zhou, Jiazhen Cui, Wenfa Huang, Mingming Zhang, Lei Wang, Lixin Wang, Delin Kong, He Huang, Yongxian HU

Blood (2023) 142 (Supplement 1): 6915.

https://doi.org/10.1182/blood-2023-187951

Published: 2023

Journal Articles

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Blood (2023) 142 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2023-185697

Published: 2023

Journal Articles

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 891.

https://doi.org/10.1182/blood-2023-186225

Published: 2023

Journal Articles

Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

Biao Zheng, Yongxian Hu, Jiqin Zhang, Mingming Zhang, Wei Li, Wenjun Wu, Jiazhen Cui, Guoqing Wei, Bing Du, Mingyao Liu, He Huang

Blood (2023) 142 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2023-185573

Published: 2023

Journal Articles

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 101.

https://doi.org/10.1182/blood-2023-185236

Published: 2023

Journal Articles

High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Yongxian Hu, Jiqin Zhang, Mingming Zhang, Wei Li, Wenjun Wu, Jiazhen Cui, Guoqing Wei, Bing Du, Mingyao Liu, He Huang

Blood (2022) 140 (Supplement 1): 7491–7492.

https://doi.org/10.1182/blood-2022-156137

Published: 2022

Journal Articles

Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy

Ruimin Hong, Linghui Zhou, Ye Meng, Mingming Zhang, Houli Zhao, Jiazhen Cui, Simao Huang, Yongxian Hu, He Huang

Blood (2022) 140 (Supplement 1): 6354–6355.

https://doi.org/10.1182/blood-2022-164955

Published: 2022

Journal Articles

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

Jingjing Feng, Yongxian Hu, Mingming Zhang, Heng Cao, Yini Ke, Huijun Xu, Jiazhen Cui, Yanlei Zhang, Alex Hongsheng Chang, Jin Lin, Guoqing Wei, He Huang

Blood (2022) 140 (Supplement 1): 10335–10336.

https://doi.org/10.1182/blood-2022-169265

Published: 2022

Journal Articles

LKB1 Coordinates Metabolic Pathways to Maintain Homeostasis of Haematopoietic Stem Cells and Regulate Erythropoiesis

Shijie Zhang, Yuanlin Xu, Mingming Zhang, Jingxin Zhang, Peijun Jia, Yudong Li, Lulu Duan, Yan Li, Huan Zhang, Yating Li, Xiaoli Qu, Lixiang Chen, Xiuli An

Blood (2021) 138 (Supplement 1): 920.

https://doi.org/10.1182/blood-2021-152342

Published: 2021

Journal Articles

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, MD, Yali Zhou, Mingming Zhang, MD, Wengang Ge, Yi Li, MD, Li Yang, MD, Guoqing Wei, MD, Lu Han, Hao Wang, Xingwang Zhang, PhD, Jiangtao Ren, PhD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-142262

Published: 2020

Journal Articles

Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

Hengwei Wu, MD, Jimin Shi, MD, Yi Luo, MD, Yamin Tan, MD, Mingming Zhang, MD, Xiaoyu Lai, MD, Jian Yu, MD, Lizhen Liu, MD, Huarui Fu, MD, He Huang, MD PhD, Yanmin Zhao, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141561

Published: 2020

NARROW

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2 ) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Targeting Mitophagy Enhances Cytotoxicity of Autologously-Derived CAR-T Cells

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

Characteristics of Central Nervous System Relapse after CD19 CAR-T Cell Therapy in R/R NHL

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

LKB1 Coordinates Metabolic Pathways to Maintain Homeostasis of Haematopoietic Stem Cells and Regulate Erythropoiesis

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only